Capsulution Announces Further Fundamental Patent Grant is Imminent
Complete the form below to unlock access to ALL audio articles.
Following a recent notice from the European Patent Office, Capsulution Nanoscience AG has announced that a further fundamental patent grant for its nano- and microencapsulation technology - known as the LBL-Technology® - is imminent.
The patent with the number EP 1064087 covers the manufacture of multifunctional nano- and micron-sized capsules.
The tiny capsules can be filled with pharmaceutical drug compounds as well as with other active substances.
On the basis of the LBL-Technology® Capsulution develops advanced drug delivery systems, which bring drugs more safely and effectively to the right site of the body.
"This patent grant will secure the sustainability and the defence of our competitive advantage in the field as one of the leading developers of nano- and microcapsules intended for life science applications," said Dr. Andreas Voigt, Chief Scientific Officer of Capsulution Nanoscience.
"Finally, we can support our industrial clients, who demand for highly differentiated products in the market, which can be sustained over a long period of time."
The LBL-Technology® is designed to represent a versatile encapsulation system. For the actual encapsulation, a wide range of FDA-approved polymers can be used.
In addition, the capsules' surface can be functionalized to suit a targeted release in the human body.
